CrystecPharma has opened a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility in Haimen City, Jiangsu Province, China.
CrystecPharma, a pharmaceutical crystal and particle engineering company, has opened a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility in Haimen City, Jiangsu Province, China.
According to a March 31, 2021 press release, the R&D center was established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform—an initiative jointly funded by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the Haimen government. The platform is aimed at accelerating pharmaceutical product innovation underpinned by advanced pharmaceutical excipients and drug delivery technologies. Crystec’s proprietary supercritical fluid technology, mSAS, will play a role in enabling the development of new therapeutics, creation of value-added medicines, and in the simplification of formulations and manufacturing processes.
“We are delighted to open our new facility in Haimen, a project credited to the collaborative efforts of SIMM, Chinese Academy of Sciences, and the Haimen government,” said Qun Shao, Crystec’s chief operations officer, in the press release. “This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China.”
Source: CrystecPharma
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.